jetcityimage
Eli Lilly’s (NYSE:LLY) popular weight loss therapy, tirzepatide, has officially come out of shortage in the U.S., according to the latest data from the U.S. Food and Drug Administration (FDA) on Friday.
The update confirmed remarks from Eli Lilly’s (LLY) CEO David Ricks, who told Bloomberg News on Thursday that the ongoing shortage for the dual GLP-1/GIP receptor agonist would officially end in the coming days.
According to the FDA, tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, is no longer in short supply in the U.S.
Lilly (LLY) and its rival in the weight loss space, Novo Nordisk (NVO), have struggled to keep up with the demand for their obesity drugs in recent months, fueling shortages.
As cheaper compounded versions flooded the market, health tech company Hims & Hers Health (HIMS) capitalized on the opportunity, launching a business in May to sell copycats of Novo’s (NVO) obesity drug Wegovy.
However, according to updated federal data, three out of five dosing strengths of Wegovy remain in shortage, while there are no shortages for its sister drug, Ozempic, indicated for diabetes.
